| scholarly article | Q13442814 |
| P356 | DOI | 10.1093/EURJHF/HFS093 |
| P698 | PubMed publication ID | 22713287 |
| P50 | author | Alexandre Mebazaa | Q63107378 |
| Phillip D Levy | Q89918839 | ||
| Christina Nowack | Q114291637 | ||
| Stephen J Greene | Q125217678 | ||
| Aldo P. Maggioni | Q40310748 | ||
| Mihai Gheorghiade | Q60059386 | ||
| Gerasimos Filippatos | Q63107352 | ||
| P2093 | author name string | Roberto Ferrari | |
| Erland Erdmann | |||
| P2860 | cites work | NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential | Q24656131 |
| Structure of cinaciguat (BAY 58-2667) bound to Nostoc H-NOX domain reveals insights into heme-mimetic activation of the soluble guanylyl cyclase | Q27661554 | ||
| Clinical trials update: highlights of the scientific sessions of the XXIII Congress of the European Society of Cardiology--WARIS II, ESCAMI, PAFAC, RITZ-1 and TIME | Q28191847 | ||
| Effect of nesiritide in patients with acute decompensated heart failure | Q28242547 | ||
| HFSA 2010 Comprehensive Heart Failure Practice Guideline | Q34124756 | ||
| Evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness: the ESCAPE trial | Q34456841 | ||
| Acute heart failure syndromes: current state and framework for future research | Q34478054 | ||
| Common causes of troponin elevations in the absence of acute myocardial infarction: incidence and clinical significance | Q35770005 | ||
| Effects of tolvaptan on dyspnoea relief from the EVEREST trials | Q37343857 | ||
| Clinical trials of pharmacological therapies in acute heart failure syndromes: lessons learned and directions forward | Q37710255 | ||
| Implantable cardioverter-defibrillator implementation in acute heart failure syndromes: unanswered questions | Q37855663 | ||
| The impact of early standard therapy on dyspnoea in patients with acute heart failure: the URGENT-dyspnoea study | Q39296001 | ||
| Hemodynamic and clinical effects of tezosentan, an intravenous dual endothelin receptor antagonist, in patients hospitalized for acute decompensated heart failure | Q44505481 | ||
| Cinaciguat (BAY 58-2667) improves cardiopulmonary hemodynamics in patients with acute decompensated heart failure. | Q46006828 | ||
| Targeting heme-oxidized soluble guanylate cyclase in experimental heart failure | Q48260348 | ||
| Cardioprotective effects in aged spontaneously hypertensive rats due to chronic stimulation/activation of sGC without hypotension. | Q55211329 | ||
| A proposal to standardize dyspnoea measurement in clinical trials of acute heart failure syndromes: the need for a uniform approach | Q57630719 | ||
| P433 | issue | 9 | |
| P921 | main subject | heart failure | Q181754 |
| acute decompensated heart failure | Q4677930 | ||
| P304 | page(s) | 1056-1066 | |
| P577 | publication date | 2012-09-01 | |
| P1433 | published in | European Journal of Heart Failure | Q5017954 |
| P1476 | title | Cinaciguat, a soluble guanylate cyclase activator: results from the randomized, controlled, phase IIb COMPOSE programme in acute heart failure syndromes | |
| P478 | volume | 14 |
| Q64069313 | A novel soluble guanylate cyclase activator with reduced risk of hypotension by short-acting vasodilation |
| Q39158670 | Advances in chemical pharmacotherapy for managing acute decompensated heart failure |
| Q28084239 | Agents with vasodilator properties in acute heart failure: how to design successful trials |
| Q38184627 | An overview of recent developments in the treatment of heart failure: update from the ESC Congress 2013. |
| Q38074093 | Causes and treatment of oedema in patients with heart failure |
| Q37419185 | Cinaciguat prevents the development of pathologic hypertrophy in a rat model of left ventricular pressure overload |
| Q46300897 | Clinical and Research Considerations for Patients With Hypertensive Acute Heart Failure: A Consensus Statement from the Society for Academic Emergency Medicine and the Heart Failure Society of America Acute Heart Failure Working Group |
| Q60916640 | Comparison of the Reverse-Remodeling Effect of Pharmacological Soluble Guanylate Cyclase Activation With Pressure Unloading in Pathological Myocardial Left Ventricular Hypertrophy |
| Q39209626 | Contemporary Approaches to Modulating the Nitric Oxide-cGMP Pathway in Cardiovascular Disease |
| Q26801166 | Contemporary Drug Development in Heart Failure: Call for Hemodynamically Neutral Therapies |
| Q48283568 | Developing Drugs for Heart Failure With Reduced Ejection Fraction: What Have We Learned From Clinical Trials? |
| Q27021649 | Extending the translational potential of targeting NO/cGMP-regulated pathways in the CVS |
| Q53241855 | From comorbidities to heart failure with preserved ejection fraction: a story of oxidative stress. |
| Q38182010 | Heart failure highlights in 2012-2013. |
| Q47661369 | Identification of a soluble guanylate cyclase in RBCs: preserved activity in patients with coronary artery disease |
| Q46261374 | Irreversible activation and stabilization of soluble guanylate cyclase by the protoporphyrin IX mimetic cinaciguat. |
| Q26765931 | Is enhancing cGMP-PKG signalling a promising therapeutic target for heart failure with preserved ejection fraction? |
| Q38594785 | New medical therapies for heart failure |
| Q52738823 | Nitric Oxide-Independent Soluble Guanylate Cyclase Activation Improves Vascular Function and Cardiac Remodeling in Sickle Cell Disease. |
| Q49501122 | Nitric oxide signalling in cardiovascular health and disease. |
| Q38202895 | Novel drug targets in clinical development for heart failure. |
| Q38073647 | Novel pharmacologic therapies in development for acute decompensated heart failure |
| Q39024203 | Novel sGC Stimulators and sGC Activators for the Treatment of Heart Failure |
| Q38072635 | Novel vasodilators in heart failure |
| Q37058596 | Phenotype-Specific Treatment of Heart Failure With Preserved Ejection Fraction: A Multiorgan Roadmap. |
| Q30251531 | Potential new drug treatments for congestive heart failure |
| Q45904891 | Progress or lack of progress in hospitalized heart failure. |
| Q88711524 | Pulmonary Oedema-Therapeutic Targets |
| Q48640874 | Rationale and design of the SOluble guanylate Cyclase stimulatoR in heArT failurE Studies (SOCRATES). |
| Q27024762 | Reactive Oxygen-Related Diseases: Therapeutic Targets and Emerging Clinical Indications |
| Q57822514 | Reassessing the Role of Surrogate End Points in Drug Development for Heart Failure |
| Q38202115 | Redox signaling as a therapeutic target to inhibit myofibroblast activation in degenerative fibrotic disease |
| Q48270850 | Role of soluble guanylate cyclase in renal hemodynamics and autoregulation in the rat. |
| Q38868193 | Similar hemodynamic decongestion with vasodilators and inotropes: systematic review, meta-analysis, and meta-regression of 35 studies on acute heart failure |
| Q38818645 | Soluble Guanylate Cyclase Stimulators and Activators: Novel Therapies for Pulmonary Vascular Disease or a Different Method of Increasing cGMP? |
| Q55436230 | Structure/function of the soluble guanylyl cyclase catalytic domain. |
| Q38180766 | Structures of soluble guanylate cyclase: implications for regulatory mechanisms and drug development |
| Q47667272 | The Role of Nitroglycerin and Other Nitrogen Oxides in Cardiovascular Therapeutics |
| Q27024279 | The cGMP signaling pathway as a therapeutic target in heart failure with preserved ejection fraction |
| Q38130465 | The chemistry and biology of soluble guanylate cyclase stimulators and activators |
| Q38072257 | The disconnect between phase II and phase III trials of drugs for heart failure |
| Q38237577 | The role of intravenous vasodilators in acute heart failure management |
| Q43119916 | The sGC stimulator riociguat inhibits platelet function in washed platelets but not in whole blood |
| Q36234790 | The soluble guanylate cyclase activator cinaciguat prevents cardiac dysfunction in a rat model of type-1 diabetes mellitus |
| Q39268911 | Therapeutic Targeting of PDEs and PI3K in Heart Failure with Preserved Ejection Fraction (HFpEF). |
| Q38214097 | Vasodilators in Acute Heart Failure: Review of the Latest Studies |
| Q38123740 | What's new in the treatment of acute heart failure? |
Search more.